Heparin-induced osteoporosis and pregnancy

Current Opinion in Pulmonary Medicine

Volumn 14, Issue 5, 2008, Pages 403-407

  Le Templier, Genevieve ^a   Rodger, Marc A ^a,b,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Bone density; Low molecular weight heparin; Osteoporosis; Pregnancy; Thromboprophylaxis

Indexed keywords

CALCIUM ION; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

BONE DEMINERALIZATION; BONE DENSITY; CALCIFICATION; CELL ACTIVITY; CLINICAL TRIAL; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOPOROSIS; PREGNANCY; PREGNANCY OUTCOME; PROPHYLAXIS; PUERPERIUM; REVIEW; RISK FACTOR; SPINE; THROMBOEMBOLISM; THROMBOPHILIA; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG EFFECT; FEMALE; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY COMPLICATION;

BONE DENSITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; OSTEOPOROSIS; PREGNANCY; PREGNANCY COMPLICATIONS; RISK FACTORS; THROMBOEMBOLISM;

EID: 53149109011     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3283061191     Document Type: Review

References (46)

1. Peck WA, Burckhardt P, Christiansen C, et al. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94:646-650.
2. Assessment of fracture risk and its application to screening for postmeno-pausal osteoporosis: report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 843:1-129.
3. Gennari C, Martini G, Nuti R. Secondary osteoporosis. Aging (Milano) 1998; 10:214-224.
4. Nelson-Piercy C, Letsky EA, de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixtyone women at high risk. Am J Obstet Gynecol 1997; 176:1062-1068.
5. Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001; 119 (Suppl):122S-131S.
6. Nordin BEC, Roper A. Post pregnancy osteoporosis: a syndrome? Lancet 1955; 1:431-434.
7. Khovidhunkit W, Epstein S. Osteoporosis in pregnancy. Osteoporos Int 1996; 6:345-354.
8. Smith R, Athanasou NA, Ostlere SJ, Vipond SE. Pregnancy-associated osteoporosis. QJM 1995; 88:865-878.
9. KhastgirG,StuddJ.Pregnancy-associatedosteoporosis.BrJObstet Gynaecol 1994; 101:836-838.
10. Khastgir G,Studd JW, King H, et al. Changesin bone density and biochemical markers of bone turnover in pregnancy-associated osteoporosis. Br J Obstet Gynaecol 1996; 103:716-718.
11. Sowers M, Crutchfield M, Jannausch M, et al. A prospective evaluation of bone mineral change in pregnancy. Obstet Gynecol 1991; 77:841-845.
12. Holmberg-Marttila D, SievanenH, Tuimala R.Changes in bone mineral density during pregnancy and postpartum: prospective data on five women. Osteoporos Int 1999; 10:41-46.
13. Drinkwater BL, Chesnut CH III. Bone density changes during pregnancy and lactation in active women: a longitudinal study. Bone Miner 1991; 14:153-160.
14. Black AJ, Topping J, Durham B, et al. A detailed assessment of alterations in bone turnover, calcium homeostasis, and bone density in normal pregnancy. J Bone Miner Res 2000; 15:557-563.
15. Naylor KE, Iqbal P, Fledelius C, et al. The effect of pregnancy on bone density and bone turnover. J Bone Miner Res 2000; 15:129-137.
16. Dunne F, Walters B, Marshall T, Heath DA. Pregnancy associated osteoporosis. Clin Endocrinol (Oxf) 1993; 39:487-490.
17. Phillips AJ, Ostlere SJ, Smith R. Pregnancy-associated osteoporosis: does the skeleton recover? Osteoporos Int 2000; 11:449-454.
18. Nelson-Piercy C. Hazards of heparin: allergy, heparin-induced thrombocyto-penia and osteoporosis. Baillieres Clin Obstet Gynaecol 1997; 11:489-509.
19. Griffith GC, Nichols G Jr, Asher JD, Flanagan B. Heparin osteoporosis. JAMA 1965; 193:91-94.
20. Nelson-Piercy C. Heparin-induced osteoporosis in pregnancy. Lupus 1997; 6:500-504.
21. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993; 168:1265-1270.
22. Barbour LA, Kick SD, Steiner JF, et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 1994; 170:862-869.
23. Dahlman TC, Sjoberg HE, Ringertz H. Bone mineral density during long-term prophylaxiswithheparininpregnancy.AmJObstetGynecol1994; 170:1315-1320.
24. Douketis JD, Ginsberg JS, Burrows RF, et al. The effects of long-term heparin therapy during pregnancy on bone density: a prospective matched cohort study. Thromb Haemost 1996; 75:254-257.
25. Gould MK, Dembitzer AD, Doyle RL, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130:800-809.
26. Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. BMJ 1994; 309:299-304.
27. Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins: a meta-analysis. Arch Intern Med 1995; 155:601-607.
28. Siragusa S, Cosmi B, Piovella F, et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996; 100:269-277.
29. Lindmarker P, Holmstrom M. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis: a feasibility and health economic study in an outpatient setting. J Intern Med 1996; 240:395-401.
30. Koopman MM, PrandoniP, Piovella F,et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group [see comments] [published erratum appears in N Engl J Med 1997 Oct 23;337(1 7):1251 ]. N Engl J Med 1996; 334:682-687.
31. Levine MN, Gent M, Hirsh J, et al. A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med 1996; 334:677-681.
32. Harrison L, McGinnis J,Crowther M, et al. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med 1998; 158:2001-2003.
33. Tillman DJ, Charland SL, Witt DM. Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization. Arch Intern Med 2000; 160:2926-2932.
34. Wells PS, Kovacs MJ, Bormanis J, et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection. Arch Intern Med 1998; 158:1809-1812.
35. Frydman AM, Bara L, Le Roux Y, et al. The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol 1988; 28:609-61 8.
36. Pettila V, Kaaja R, Leinonen P, et al. Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thromb Res 1999; 96:275-282.
37. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106:401-407.
38. Muir JM, Hirsh J, Weitz JI, et al. A histomorphometric comparison of the effects of heparin and low- molecular-weight heparin on cancellous bone in rats. Blood 1997; 89:3236-3242.
39. Hunt BJ, Doughty HA, Majumdar G, et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost 1997; 77:39-43.
40. Melissari E, Parker CJ, Wilson NV, et al. Use of low molecular weight heparin in pregnancy. Thromb Haemost 1992; 68:652-656.
41. Casele HL, Laifer SA. Prospective evaluation of bone density in pregnant women receiving the low molecular weight heparin enoxaparin sodium. J Matern Fetal Med 2000; 9:122-125.
42. Shefras J, Farquharson RG. Bone density studies in pregnant women receiving heparin. Eur J Obstet Gynecol Reprod Biol 1996; 65:171-174.
43. Backos M, Rai R, Thomas E, et al. Bone density changes in pregnant women treated with heparin: a prospective, longitudinal study. Hum Reprod 1999; 14:2876-2880.
44. Laskin C, Ginsberg J, Farine D, et al. Low molecular weight heparin and ASA therapy in women with autoantibodies and unexplained recurrent fetal loss (U-RFL). Am J Obstet Gynecol 1997; 176:S125.
45. Pettila V, Leinonen P, Markkola A, et al. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 2002; 87:182-186.
46. Rodger MA, Kahn SR, Cranney A, et al. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. J Thromb Haemost 2007; 5:1600-1606. 47 Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005; 20:1185-1194.